Advancing single-shot vaccine design through AI and computational models

Abstract

Single-dose vaccines represent a transformative advancement in immunization, offering durable and effective immunity through a single administration. The incorporation of artificial intelligence (AI) and computational modeling has significantly enhanced the development of these vaccines. This review provides an in-depth analysis of AI’s contributions to epitope identification, immunogenicity prediction, optimization of vaccine stability, and controlled-release mechanisms. Furthermore, real-world applications are examined through case studies that demonstrate the impact of AI-driven methodologies in accelerating and refining vaccine development.

Highlights

AI-driven advancements have revolutionized single-dose vaccine development enabling precise epitope identification, immunogenicity prediction, and stability optimization. This review highlights cutting-edge methodologies and real-world case studies that show AI’s transformative role of AI in enhancing vaccine efficacy and accelerating immunization innovations.

Introduction

The increasing demand for single-shot vaccines reflects their potential to address critical challenges in immunization programs. Unlike multidose regimens, single-shot formulations streamline vaccination schedules, facilitating broader population coverage, particularly in regions with limited healthcare resources. These vaccines alleviate logistical hurdles such as the need for multiple storage and transportation arrangements, thereby reducing the strain on healthcare systems. Additionally, by eliminating the need for follow-up doses, single-shot vaccines can significantly enhance patient compliance, which is an essential factor for managing infectious disease outbreaks and pandemics. Their practicality and efficiency position them as transformative tools for advancing global health initiatives [1].

However, despite these advantages, the development of single-shot vaccines presents significant scientific and technical challenges. Achieving a durable and robust immune response from a single dose requires meticulous antigen design and delivery optimization. Traditional methodologies often fail to meet these demands, particularly when rapidly addressing mutated pathogens or diverse antigenic targets. These complexities have spurred the adoption of advanced technologies such as artificial intelligence (AI) and computational modeling in vaccine research. These innovative tools enable researchers to gain deeper insights into molecular interactions, thereby facilitating the identification of highly immunogenic antigen candidates [2].

AI-powered systems have transformed the antigen selection landscape by analyzing extensive datasets to predict epitopes capable of eliciting potent immune responses. Machine learning models simulate immune system behavior, aiding in the optimization of antigen stability and selection of delivery mechanisms designed for sustained antigen release. Sustained antigen presentation is critical to achieve long-term immunity with single-shot vaccines. In addition, computational models refine vaccine formulations to ensure their stability across varying storage conditions, which is vital for global distribution in diverse environments.

The integration of AI and computational tools into vaccine development not only addresses these complexities, but also accelerates the entire process. By enabling in silico testing and hypothesis validation, these technologies reduce reliance on expensive and time-consuming laboratory experiments. Consequently, AI and computational modeling have redefined traditional approaches, offering a more streamlined and efficient pathway for vaccine innovation. By leveraging these advancements, researchers will be better equipped to overcome the unique challenges of single-shot vaccine development, paving the way for successful implementation on a global scale [3].

Summary of AI Tools in Vaccine Development

Epitope prediction tools

Artificial intelligence (AI) has revolutionized epitope identification by analyzing vast datasets to pinpoint regions on antigens capable of eliciting strong immune responses. Machine learning (ML) algorithms such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs) have been employed to predict both linear and conformational epitopes. CNNs can be used to identify spatial hierarchies and structural patterns in high-dimensional data, such as protein structures, making them ideal for predicting conformational epitopes by analyzing the 2D or 3D structural features of antigens. Their use of convolutional filters and pooling layers reduces complexity while preserving key features, enabling efficient large-scale predictions. RNNs, on the other hand, are well-suited for analyzing sequential data, such as amino acid sequences, and capturing dependencies across residues to identify linear epitopes. Advanced variants, such as Long Short-Term Memory (LSTM) and Gated Recurrent Units (GRUs) further enhance their ability to model long-range dependencies, making CNNs and RNNs indispensable tools for accurate and comprehensive epitope predictions.

NetMHCpan: NetMHCpan is a sophisticated computational tool designed to predict binding affinities between peptides and human leukocyte antigen (HLA) molecules. Advanced deep learning algorithms offer high accuracy in identifying peptide sequences that are likely to elicit immune responses by binding to specific HLA alleles. This capability is instrumental in epitope mapping for vaccine design and enables researchers to focus on the most promising antigen candidates for immunogenicity studies. The robust predictive power of NetMHCpan makes it a critical resource in immunoinformatics and personalized medicine [4].

IEDB (Immune Epitope Database): The Immune Epitope Database (IEDB) is a comprehensive resource that provides a wide array of tools for predicting B-cell and T-cell epitopes. These epitopes, which are specific antigen regions recognized by the immune system, are crucial for vaccine development and immunotherapy. IEDB offers prediction tools for both linear epitopes (amino acid sequences that directly bind to immune receptors) and conformational epitopes (formed by the three-dimensional structure of the antigen). These tools utilize advanced algorithms and data derived from experimental studies to predict the binding affinity of the epitopes to major histocompatibility complex (MHC) molecules essential for T cell activation as well as their potential to elicit antibody responses. The IEDB is continually updated with experimental data, enhancing its predictive accuracy and providing valuable insights for researchers working on the development of vaccines and immunotherapies targeting various infectious diseases and cancers [5].

DeepVacPred: DeepVacPred is an advanced computational tool that leverages deep-learning techniques, specifically neural networks, to predict immunogenic peptides for vaccine development. DeepVacPred identifies sequences with the potential to induce robust immune activation by analyzing large datasets of known peptide sequences and their associated immune responses. This tool integrates various features, including peptide-HLA binding affinities, which are crucial for determining the likelihood of a peptide eliciting a response from the immune system. The ability of DeepVacPred to predict both T-cell- and B-cell epitopes allows researchers to design more targeted and effective vaccines, especially for emerging pathogens or diseases for which traditional vaccine development methods may be less effective. Because of its high accuracy and efficiency, DeepVacPred supports the rational design of vaccines by significantly reducing the time and resources required to identify promising immunogenic candidates [6].

Protein structure prediction tools

AlphaFold (DeepMind): AlphaFold (DeepMind) is an AI-powered tool developed by DeepMind that accurately predicts the three-dimensional (3D) structures of proteins. By leveraging deep-learning algorithms, AlphaFold can analyze the amino acid sequence of a protein and predict its precise 3D shape with remarkable accuracy. This breakthrough has significantly advanced structural biology by providing detailed structural models of proteins that were previously difficult to obtain using traditional experimental methods, such as X-ray crystallography or cryo-electron microscopy. The ability to predict protein structures with high precision is crucial for vaccine development. In the context of antigen design, AlphaFold predictions can be used to identify the key regions of pathogen proteins that are likely to trigger a strong immune response. This knowledge will allow researchers to focus on the most promising epitopes for designing novel vaccines. Additionally, this tool aids in understanding protein-folding mechanisms and the stability of vaccine candidates, contributing to the optimization of vaccine formulations. AlphaFold has accelerated the vaccine design process, particularly for emerging infectious diseases, by enabling faster and more informed decisions with respect to antigen selection and engineering.

RoseTTAFold: RoseTTAFold is an advanced AI-based tool designed to predict protein structure and serves as a complement to AlphaFold. Developed by the Baker Lab at the University of Washington, RoseTTAFold leverages deep learning techniques to model protein folding and predict three-dimensional structures from amino acid sequences. The key innovation is its ability to handle large-scale structural prediction tasks with high efficiency and accuracy. RoseTTAFold integrates a multistage approach using a neural network architecture to predict the spatial relationships between residues in a protein sequence, facilitating more accurate structure predictions, even for complex proteins. Although AlphaFold has achieved remarkable success in the field of protein structure prediction, RoseTTAFold provides an additional layer of validation through its distinct modeling approach. By combining both tools, researchers can cross-validate protein structures and enhance reliability of the predicted results. The capacity of RoseTTAFold to predict not only single-chain proteins but also protein complexes makes it an invaluable asset in drug discovery and vaccine design, where understanding protein-protein interactions and functional conformations is essential. They are used in various fields of structural biology, and contribute to a deeper understanding of protein functions and interactions with respect to health and disease.

Vaccine stability and formulation tools

PolymiRTS: PolymiRTS is an advanced computational tool designed to predict the stability and release profiles of RNA vaccines encapsulated in nanoparticles. It leverages machine learning algorithms and molecular dynamics simulations to model interactions between RNA molecules and nanoparticle carriers, such as lipid nanoparticles (LNPs). This enables the prediction of key characteristics such as RNA degradation rates, encapsulation efficiency, and kinetics of antigen release under various environmental conditions such as temperature and pH fluctuations. By providing insights into the stability of RNA formulations and optimizing their release mechanisms, polymiRTS can accelerate the development of RNA-based vaccines with enhanced efficacy and longer shelf life. Their application is particularly valuable for improving the design of single-dose RNA vaccines and ensuring their effectiveness throughout storage and distribution, which is critical for global vaccination efforts.

LipoDesign: LipoDesign is an AI-powered platform designed to optimize the formulation of lipid nanoparticles (LNPs) in drug and vaccine delivery systems. LNPs have become a critical component in the development of mRNA vaccines as they facilitate the encapsulation and efficient delivery of mRNA to cells. LipoDesign leverages machine learning algorithms to predict and fine-tune the physicochemical properties of lipid formulations such as particle size, surface charge, and encapsulation efficiency, which are essential for enhancing the stability and performance of the delivered mRNA or other therapeutic agents. By analyzing extensive datasets from previous LNP formulations, LipoDesign AI models can identify patterns that correlate specific lipid compositions with successful delivery outcomes. This platform enables researchers to design lipid formulations that provide optimal stability during storage, facilitate efficient cellular uptake, and minimize potential toxicity. It also helps in selecting the best lipid material that will allow for controlled release and sustained therapeutic effects. The ability of LipoDesign to rapidly iterate and predict formulation outcomes significantly reduces the trial-and-error process traditionally involved in nanoparticle design, thereby accelerating the development of lipid nanoparticle-based vaccines and therapies.

This AI-guided approach not only improves the quality and efficiency of LNP formulations, but also enhances scalability, making it a valuable tool for large-scale vaccine production. LipoDesign has proven to be instrumental in developing successful vaccines, such as mRNA vaccines for COVID-19, and has the potential to play a crucial role in future vaccine and gene therapy innovations [7].

Immunogenicity prediction

Vaxign-ML: Vaxign-ML is an advanced computational tool that merges machine-learning techniques with reverse vaccinology to predict potential immunogenic antigens for vaccine development. By leveraging large datasets and machine learning algorithms, Vaxign-ML can identify bacterial and viral antigens with a high likelihood of eliciting a strong immune response. This system analyzes various features of microbial proteins, including sequence motifs, structural properties, and evolutionary conservation, to prioritize candidates for further experimental validation. This tool enhances the speed and accuracy of antigen discovery, enabling researchers to efficiently select targets that are most likely to induce humoral and cellular immunity. Vaxign-ML is particularly useful for designing vaccines against pathogens with limited genomic information, thereby accelerating the development of new vaccines in response to emerging infectious diseases.

iPred: The iPred is a computational tool designed to predict T-cell epitope immunogenicity, specifically focusing on the interactions between peptides and T-cell receptors. It utilizes machine learning algorithms to analyze peptide sequences and predict their ability to stimulate immune responses. By evaluating the binding affinity of peptides to major histocompatibility complex (MHC) molecules, iPred can be used to identify promising T cell epitopes for inclusion in vaccine candidates. This tool is highly valuable in immunoinformatics, assisting researchers in selecting epitopes that are likely to induce strong T cell-mediated immunity, which is crucial for the development of effective vaccines. The iPred contributes to the understanding of immune system interactions and facilitates the design of vaccines with enhanced specificity and potency. This makes them an important resource for personalized medicine and the development of vaccines targeting infectious diseases and cancers [8].

Adjuvant selection

AdjuPred: AdjuPred is an advanced machine learning (ML)-based tool designed to predict the compatibility and efficacy of adjuvants in enhancing immune responses when combined with specific antigens. The platform leverages vast datasets of known antigen-adjuvant interactions and employs sophisticated ML algorithms to identify potential adjuvant candidates that could optimize immune activation. Adjuvants play a crucial role in improving the potency and duration of vaccine response, particularly when used with subunit vaccines or poorly immunogenic antigens. By integrating predictive models, AdjuPred enables researchers to assess the potential effectiveness of various adjuvants, thereby guiding the selection of optimal adjuvant-antigen combinations for specific vaccine formulations. This tool incorporates several factors, including the physicochemical properties of the adjuvant, its mechanism of action, and immune system response pathways, to predict the most promising combinations. This helps streamline the process of adjuvant development by reducing trial-and-error and improving the likelihood of producing highly effective vaccines. The predictive capabilities of AdjuPred enhance vaccine design by enabling rational selection of adjuvants tailored to specific antigen characteristics, ultimately improving the efficacy and safety profiles of the vaccines.

In-silico Adjuvant Discovery Platform: This platform utilizes artificial intelligence (AI) to accelerate the identification of novel adjuvant candidates. Adjuvants are critical for enhancing the immune response to vaccines, and their selection often requires extensive trial and error. Traditional methods for adjuvant discovery are time-consuming and expensive; however, AI-driven platforms streamline this process by predicting the optimal adjuvants for specific antigens.

These platforms use machine-learning algorithms to analyze large datasets of known adjuvants and their effects on immune responses, identifying patterns and relationships that may not be immediately apparent. By simulating the interactions between antigens and adjuvants, AI models can predict which adjuvants are likely to enhance immunogenicity and improve vaccine efficacy and safety profiles. Additionally, AI tools can assess the compatibility of different adjuvants with various vaccine formulations and predict their potential impact on stability and efficacy under diverse conditions.

The in silico adjuvant discovery platform has accelerated the discovery of novel non-traditional adjuvants that may offer superior performance compared to existing options. These platforms are particularly valuable in the development of vaccines for emerging infectious diseases, where rapid responses are needed and conventional adjuvants may not be effective. By integrating AI into the adjuvant discovery process, researchers can quickly identify promising candidates, ultimately contributing to the development of more effective and tailored vaccines [9] (Table 1).

Table 1.Overview of advanced AI-powered tools for vaccine design and development

Category	Tool	Description	Applications
Epitope prediction tools	NetMHCpan [22]	Predicts binding affinities between peptides and HLA molecules using deep learning algorithms. Identifies peptide sequences likely to elicit immune responses.	Epitope mapping for vaccine design, personalized medicine.
	IEDB [23]	Provides tools for predicting B-cell and T-cell epitopes. Predicts binding affinities to MHC molecules and potential antibody responses using experimental and computational data.	Vaccine development, immunotherapy, targeting infectious diseases and cancers.
	DeepVacPred [24]	Utilizes deep learning to predict immunogenic peptides for vaccine development. Analyzes peptide-HLA binding affinities and immune response data.	Designing vaccines for emerging pathogens, reducing time and cost in epitope identification.
Protein structure prediction tools	AlphaFold (DeepMind)	Predicts 3D protein structures with high accuracy using deep learning algorithms. Facilitates identification of epitopes and protein folding mechanisms.	Antigen design, understanding protein stability, optimizing vaccine formulations.
	RoseTTAFold [3]	Predicts protein 3D structures and protein complexes using deep learning. Provides a complementary approach to AlphaFold, enabling cross-validation.	Drug discovery, vaccine design, understanding protein-protein interactions
Vaccine stability and formulation tools	PolymiRTS [25]	Predicts stability and release profiles of RNA vaccines encapsulated in nanoparticles. Models RNA-nanoparticle interactions to optimize vaccine formulations.	RNA vaccine development, improving stability and release kinetics.
	LipoDesign [26]	Optimizes lipid nanoparticle formulations for mRNA vaccine delivery using machine learning. Predicts physicochemical properties for efficient delivery and stability.	Developing LNP-based vaccines and therapies, including COVID-19 vaccines.
Immunogenicity prediction	Vaxign-ML	Combines machine learning with reverse vaccinology to identify bacterial and viral antigens likely to elicit strong immune responses.	Designing vaccines for pathogens with limited genomic information, emerging infectious diseases.
Adjuvant selection	AdjuPred	ML-based tool predicting antigen-adjuvant compatibility and efficacy. Assesses physicochemical properties and mechanisms of adjuvants.	Streamlining adjuvant selection, optimizing antigen-adjuvant combinations, improving vaccine efficacy and safety.

HLA: Human leukocyte antigens; MHC: Major histocompatibility complex.

Machine Learning Models for Optimizing Vaccine Stability and Release Profiles

Stability prediction

Vaccine stability is a vital consideration, particularly for single-shot formulations, because it ensures long-term efficacy and safety throughout storage and distribution. Artificial intelligence (AI) models play a crucial role in predicting and optimizing various aspects of vaccine stability. These models simulate protein folding and aggregation tendencies, helping researchers understand how antigens behave under different conditions. By identifying potential issues early, AI can help design more stable formulations that are less prone to degradation.

AI is also utilized to predict the degradation pathways of vaccine components, such as proteins and adjuvants, under varying environmental conditions, such as temperature and pH. These insights allow development of vaccines that maintain their potency even in challenging storage environments, which are especially important for global distribution, where cold chain infrastructure may be limited. Additionally, AI models are applied to assess the encapsulation efficiency in delivery systems, such as liposomes or nanoparticles, ensuring that the active ingredient is effectively protected and delivered to target cells without premature degradation.

DeepMind’s AlphaFold has revolutionized protein structure prediction and is a prominent example of the application of artificial intelligence (AI) in structural biology is DeepMind’s AlphaFold, which has revolutionized protein structure prediction. The ability of AlphaFold to accurately predict protein folding enables researchers to anticipate potential stability issues and optimize antigen structures to improve the stability of vaccine formulations. This capability is critical for designing vaccines that maintain their integrity and function, even when exposed to various stressors during production, transport, and storage. Through the integration of AI, the vaccine development process has become more efficient, paving the way for reliable and stable single-shot vaccines.

Controlled release profiles

Variational Autoencoders (VAEs) and other machine learning models are increasingly used to optimize the release kinetics of antigens in single-shot vaccines. These models focus on designing nanoparticle delivery systems that enable the controlled and sustained release of antigens, which is crucial for achieving long-lasting immunity from a single dose. By analyzing the interactions between the antigens and delivery platforms, VAE-guided models can predict the most effective formulations for maintaining antigen stability and ensuring gradual release over time [10].

In particular, VAEs are generative models that can create novel nanoparticle designs with specific characteristics such as size, surface charge, and biodegradability, which are optimized for sustained release. These properties allow better control over how the antigen is released into the immune system, thereby enhancing the efficacy of the vaccine by promoting a prolonged immune response. Recent applications of VAEs have been successful in designing biodegradable polymer matrices and liposomes that encapsulate antigens, protecting them from degradation while ensuring controlled release. This approach minimizes the need for multiple doses, making it especially advantageous for developing efficient single-shot vaccines that require fewer resources and simplifying global vaccination campaigns [11].

Case Studies of AI-Driven Vaccine Development Programs

COVID-19 mRNA vaccines

The rapid development of the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines has highlighted the transformative role of artificial intelligence (AI) in vaccine development. AI is crucial for the identification of immunogenic epitopes in the SARS-CoV-2 spike protein, which is a critical target for inducing immunity. Using AI-driven immunoinformatics, researchers have analyzed vast datasets to predict which regions of the spike protein would elicit strong immune responses. This computational approach significantly accelerated the process of selecting the most promising epitopes, ensuring that the vaccines targeted the most effective viral components for immune activation.

Additionally, AI plays a pivotal role in the optimization of lipid nanoparticle (LNP) formulations for mRNA delivery. Lipid nanoparticles are essential for protecting the fragile mRNA strands and facilitating their delivery to human cells. AI models have helped refine lipid compositions and improve stability, size, and release characteristics of the nanoparticles, which are critical for ensuring efficient mRNA translation and a sustained immune response. The ability to predict and fine-tune these formulations in silico drastically shortens the development timeline, allowing for the rapid deployment of these vaccines. This combination of AI-driven epitope selection and LNP optimization has been instrumental in the rapid success of mRNA vaccines during the global COVID-19 pandemic [12].

Malaria single-shot vaccine

The R21/Matrix-M malaria vaccine represents a significant advancement in malaria immunization and AI tools play a pivotal role in its design. Researchers have utilized artificial intelligence models to optimize the antigen structure of vaccines, enhancing their ability to trigger a robust immune response after a single administration. AI-driven simulations have helped refine the combination of antigens that would most effectively induce immunity against Plasmodium falciparum, the parasite responsible for malaria. Additionally, AI algorithms were employed to identify and select the most suitable adjuvants that work synergistically with the antigen. The matrix-M adjuvant, chosen for its ability to boost immune responses, was optimized using computational models to ensure compatibility with the vaccine and its efficacy in a single-dose formulation. This combination was crucial for achieving the high efficacy rates observed in clinical trials, where the vaccine demonstrated strong protection against malaria in a single-dose regimen.

AI tools not only expedited the design process but also enabled the precise fine-tuning of vaccine components, addressing the challenges of stability and antigen presentation. Consequently, the R21/Matrix-M vaccine has become a promising candidate for the fight against malaria, demonstrating how AI can revolutionize vaccine development for complex diseases [13].

AI in tuberculosis vaccine design

Machine learning (ML) approaches have shown great promise for the design of tuberculosis (TB) vaccines, particularly for the development of multi-epitope constructs aimed at single-dose formulations. Tuberculosis remains a major global health challenge, and the need for more effective and long-lasting vaccines is critical to achieve worldwide eradication. ML models have been employed to analyze vast datasets of TB-specific antigens and their interactions with immune system components, enabling the identification of highly immunogenic epitopes that drive potent immune responses.

Through pattern recognition and data mining, ML algorithms can predict epitopes from various TB proteins that are most likely to stimulate both T-cell- and B-cell responses. By combining multiple epitopes into a single multi-epitope vaccine construct, these designs aim to provide broad protection against different M. tuberculosis strains. Machine learning models also assist in optimizing vaccine formulations, ensuring that multi-epitope constructs are stable, immunogenic, and capable of eliciting durable immunity after a single administration.

Incorporating ML in TB vaccine design also enables the exploration of novel adjuvants and delivery systems, ensuring that these vaccines not only provoke a strong immune response, but are also practical for use in resource-limited settings. By predicting the most effective combinations of epitopes, adjuvants, and delivery mechanisms, AI-driven approaches offer a promising avenue for accelerating the development of single-dose TB vaccines, ultimately contributing to global eradication efforts [14].

Challenges

Although AI has demonstrated substantial promise for advancing vaccine development, several challenges must be addressed to fully realize its potential.

One of the primary hurdles is data limitations. The effectiveness of AI models relies heavily on high-quality diverse datasets for accurate predictions. Incomplete or biased data can lead to inaccurate results, thus undermining the reliability of AI-driven findings. Additionally, ensuring data diversity is critical for developing vaccines that are universally effective across different populations, by considering factors such as genetics, demographics, and preexisting health conditions.

Another significant challenge was model interpretability. AI models, particularly deep-learning systems, can operate as “black boxes”, indicating that their decision-making processes are not always transparent. For AI models to gain acceptance within regulatory frameworks, it is essential to ensure that the decision-making process is understandable and can be explained in a manner that meets regulatory standards. Regulatory agencies require a clear justification for the predictions made by AI tools, especially when they are applied to sensitive areas, such as vaccine development.

Finally, there is the issue of integration with traditional vaccine development workflows. While AI offers transformative capabilities, its integration into established processes is often complex. Traditional vaccine development methods involve numerous experimental phases and alignment with AI-driven approaches requires substantial adaptation and coordination. Ensuring seamless collaboration between computational tools and experimental procedures is crucial for optimizing the development timeline and the effectiveness of new vaccines.

Addressing these challenges is vital for advancing AI applications in vaccine research and achieving broader adoption in the field. As technology matures, continuous efforts to overcome these obstacles will help enhance the accuracy, reliability, and acceptance of AI-driven vaccine innovations [15].

Future Prospects of AI in Vaccine Development

Universal vaccine design

AI holds significant promise for the design of universal vaccines, particularly for identifying highly conserved epitopes across diverse pathogens. Traditional vaccine development often focuses on specific strains or variants that become less effective as the pathogen evolves. However, AI-driven platforms can analyze large genomic datasets to detect conserved regions of antigens that remain stable across multiple strains of viruses or bacteria. By targeting these highly conserved epitopes, AI enables the development of broad-spectrum vaccines capable of providing protection against a range of variants, improving global preparedness for future outbreaks [16, 17].

Real-time optimization for emerging variants

As new infectious disease variants, vaccines must be adapted quickly to maintain their efficacy. AI-powered adaptive models can optimize vaccine formulations in real-time by analyzing genetic data from emerging strains. Machine learning algorithms can assess the mutational landscape of pathogens and predict how these changes may affect vaccine performance. This allows for rapid adjustments in vaccine composition, ensuring that vaccines remain effective against new variants. Adaptive AI models can also simulate potential immune responses, helping prioritize which changes in vaccine design will be most beneficial for controlling outbreaks [18].

AI-driven clinical trial design

is poised to revolutionize the clinical trial process by enhancing trial design and optimizing patient recruitment. Through data mining and predictive analytics, AI can identify the most suitable candidates for clinical trials, ensuring that the trials are both efficient and representative. Furthermore, AI models can simulate trial outcomes, enabling identification of the most promising vaccine candidates before conducting costly and time-consuming in vivo trials. By predicting patient responses and monitoring real-time data, AI can streamline the approval process by providing earlier insights into efficacy and safety in the trial stages. This not only accelerates the development timeline but also improves the overall success rate of vaccine candidates [19,20,21].

Conclusion

Incorporation of AI and computational modeling into the design of single-shot vaccines has resulted in a transformative shift in vaccination strategies. AI significantly enhances the accuracy and efficiency of vaccine development by improving epitope prediction, optimizing stability, and refining release profiles. This integration paves the way for the creation of innovative vaccines that are well-equipped to address pressing global health issues. As AI technologies continue to evolve and become increasingly integrated with experimental methods, they will play a crucial role in accelerating the development of advanced single-shot vaccines.

Conflict of Interest

The Authors declare no conflict of interest.

References

• 1.   Vinukonda,  A.Single shot vaccine for multi-use: an overview. World J. Advanced Res. Reviews 2023; 18: 95–102.
• 2.   Jumper,  J.,  Evans,  R.,  Pritzel,  A.,  Green,  T.,  Figurnov,  M.,  Ronneberger,  O.,  Tunyasuvunakool,  K.,  Bates,  R.,  Žídek,  A.,  Potapenko,  A.,  Bridgland,  A.,  Meyer,  C.,  Kohl,  S. A. A.,  Ballard,  A. J.,  Cowie,  A.,  Romera-Paredes,  B.,  Nikolov,  S.,  Jain,  R.,  Adler,  J.,  Back,  T.,  Petersen,  S.,  Reiman,  D.,  Clancy,  E.,  Zielinski,  M.,  Steinegger,  M.,  Pacholska,  M.,  Berghammer,  T.,  Bodenstein,  S.,  Silver,  D.,  Vinyals,  O.,  Senior,  A. W.,  Kavukcuoglu,  K.,  Kohli,  P. and  Hassabis,  D. 2021. Highly accurate protein structure prediction with AlphaFold. Nature 596: 583–589.
• 3.   Baek,  M.,  DiMaio,  F.,  Anishchenko,  I.,  Dauparas,  J.,  Ovchinnikov,  S.,  Lee,  G. R.,  Wang,  J.,  Cong,  Q.,  Kinch,  L. N.,  Schaeffer,  R. D.,  Millán,  C.,  Park,  H.,  Adams,  C.,  Glassman,  C. R.,  DeGiovanni,  A.,  Pereira,  J. H.,  Rodrigues,  A. V.,  van Dijk,  A. A.,  Ebrecht,  A. C.,  Opperman,  D. J.,  Sagmeister,  T.,  Buhlheller,  C.,  Pavkov-Keller,  T.,  Rathinaswamy,  M. K.,  Dalwadi,  U.,  Yip,  C. K.,  Burke,  J. E.,  Garcia,  K. C.,  Grishin,  N. V.,  Adams,  P. D.,  Read,  R. J. and  Baker,  D. 2021. Accurate prediction of protein structures and interactions using a three-track neural network. Science 373: 871–876.
• 4.   Jurtz,  V.,  Paul,  S.,  Andreatta,  M.,  Marcatili,  P.,  Peters,  B. and  Nielsen,  M. 2017. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199: 3360–3368.
• 5.   Vita,  R.,  Mahajan,  S.,  Overton,  J. A.,  Dhanda,  S. K.,  Martini,  S.,  Cantrell,  J. R.,  Wheeler,  D. K.,  Sette,  A. and  Peters,  B. 2019. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 47 D1: D339–D343.
• 6.   Wang,  P.,  Hu,  Y.,  Wang,  T.,  Zhang,  X.,  Liu,  Y.,  Chen,  W.,  Li,  J. and J. and  Zhou,  F. 2022. DeepVacPred: an integrated deep learning framework for multi-epitope vaccine development. iScience 25: 104698.
• 7.   Flower,  D. R.,  Macdonald,  I. K.,  Ramakrishnan,  K.,  Durrant,  L. G.,  Davies,  M. N.,  Reddington,  J. J.,  Taylor,  R. D. and R. D. and  Andrew,  S. M. 2021. Computer-aided selection of vaccine adjuvants. Immunology 162: 95–104.
• 8.   Obermeyer,  F.,  Schaffner,  S. F.,  Jankowiak,  M.,  Barkas,  N.,  Pyle,  J. D.,  Yurkovetskiy,  L., L.,  Bosso,  M.,  Park,  D. J.,  Babadi,  M.,M., MacInnis,  B. L.,  Luban,  J.,  Sabeti,  P. C. and P. C. and  Regev,  A. 2021. Analysis of spike protein evolution and immune escape in the context of SARS-CoV-2. Cell Rep. Med. 2: 100276.
• 9.   López-Blanco,  J. R.,  Canosa-Valls,  A. J.,  Li,  Y.,  Keegan,  R. M. and R. M. and  Rigden,  D. J. 2022. Exploring protein-protein interactions with AlphaFold and RoseTTAFold. Nat. Struct. Mol. Biol. 29: 919–923.
• 10.   Sahin,  U.,  Karikó,  K. and  Türeci,  Ö. 2014. mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug Discov. 13: 759–780.
• 11.   Ullah,  M. A.,  Sun,  T.,  Khan,  A.,  Zhang,  X.,  Li,  Y.,Y., Chen,  R.,  Patel,  K.,K., Wang,  J. and J. and  Smith,  D. 2023. AI-enabled design of lipid nanoparticles for mRNA vaccines: a review. ACS Nano 17: 2923–2942.
• 12.   Polack,  F. P.,  Thomas,  S. J.,  Kitchin,  N.,  Absalon,  J.,  Gurtman,  A.,  Lockhart,  S.,  Perez,  J. L.,  Pérez Marc,  G.,  Moreira,  E. D.,  Zerbini,  C.,  Bailey,  R.,  Swanson,  K. A.,  Roychoudhury,  S.,  Koury,  K.,  Li,  P.,  Kalina,  W. V.,  Cooper,  D.,  Frenck,  R. W. Jr.,  Hammitt,  L. L.,  Türeci,  Ö.,  Nell,  H.,  Schaefer,  A.,  Ünal,  S.,  Tresnan,  D. B.,  Mather,  S.,  Dormitzer,  P. R.,  Şahin,  U.,  Jansen,  K. U.,  Gruber,  W. C., C4591001 Clinical Trial Group 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383: 2603–2615.
• 13.   Baden,  L. R.,  El Sahly,  H. M.,  Essink,  B.,  Kotloff,  K.,  Frey,  S.,  Novak,  R.,  Diemert,  D.,  Spector,  S. A.,  Rouphael,  N.,  Creech,  C. B.,  McGettigan,  J.,  Khetan,  S.,  Segall,  N.,  Solis,  J.,  Brosz,  A.,  Fierro,  C.,  Schwartz,  H.,  Neuzil,  K.,  Corey,  L.,  Gilbert,  P.,  Janes,  H.,  Follmann,  D.,  Marovich,  M.,  Mascola,  J.,  Polakowski,  L.,  Ledgerwood,  J.,  Graham,  B. S.,  Bennett,  H.,  Pajon,  R.,  Knightly,  C.,  Leav,  B.,  Deng,  W.,  Zhou,  H.,  Han,  S.,  Ivarsson,  M.,  Miller,  J.,  Zaks,  T., COVE Study Group 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384: 403–416.
• 14.   Pardi,  N.,  Hogan,  M. J.,  Porter,  F. W. and  Weissman,  D. 2018. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17: 261–279.
• 15.   Guebre-Xabier,  M.,  Patel,  N.,  Tian,  J. H.,  Zhou,  B.,  Maciejewski,  S.,  Lam,  K.,  Portnoff,  A. D.,  Massare,  M. J.,  Frieman,  M. B.,  Piedra,  P. A.,  Ellingsworth,  L.,  Glenn,  G. and  Smith,  G. 2020. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine 38: 7892–7896.
• 16.   Dagan,  N.,  Barda,  N.,  Kepten,  E.,  Miron,  O.,  Perchik,  S.,  Katz,  M. A.,  Hernán,  M. A.,  Lipsitch,  M.,  Reis,  B. and  Balicer,  R. D. 2021. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384: 1412–1423.
• 17.   Duffy,  P. E. 2021. R21/Matrix-M: a promising malaria vaccine candidate. Lancet 397: 1723–1724.
• 18.   Lurie,  N.,  Saville,  M.,  Hatchett,  R. and  Halton,  J. 2020. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382: 1969–1973.
• 19.   McFadden,  S. M.,  Malik,  A. A.,  Aguolu,  O. G.,  Willebrand,  K. S. and  Omer,  S. B. 2020. Perceptions of the adult US population regarding the novel coronavirus outbreak. PLoS One 15: e0231808.
• 20.   Lin,  L.,  Xu,  J.,  Shi,  J.,  Wang,  L. and  Zhang,  G. 2022. Advances in tuberculosis vaccine design: the role of machine learning. Front. Immunol. 13: 855140.
• 21.   Sadrbafoghi,  S.,  Mojarad,  B.,  Faghihi,  S.,  Sadrbafoghi,  S. M.,  Mohammadi,  M., and  Khosravi,  A. 2023. Artificial intelligence in vaccine development: recent advancements and challenges. Comput. Biol. Med. 156: 106659.
• 22.   Andreatta,  M. and  Nielsen,  M. 2016. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32: 511–517.
• 23.   Vita,  R.,  Overton,  J. A.,  Greenbaum,  J. A.,  Ponomarenko,  J.,  Clark,  J. D.,  Cantrell,  J. R.,  Wheeler,  D. K.,  Gabbard,  J. L.,  Hix,  D.,  Sette,  A. and  Peters,  B. 2015. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 43 D1: D405–D412.
• 24.   Hasan,  M. M.,  Islam,  R.,  Sharmin,  S.,  Khatun,  M. S.,  Kurata,  H.,  Abo-Zaid,  G.,  Tayebi,  M.,  Shami,  A., and  Moni,  M. A. 2021. Deep learning-based methods for predicting vaccine candidates from pathogenic sequences. Brief. Bioinform. 22: bbab282.
• 25.   Liu,  R.,  Bassett,  A. R. and  Butler,  M. W., eds. RNA vaccine stability and delivery simulation using machine learning and molecular dynamics approaches. Computational Vaccine Design Handbook. Elsevier; 2022.
• 26.   Hou,  X.,  Zaks,  T.,  Langer,  R. and  Dong,  Y. 2021. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6: 1078–1094.